期刊文献+

卵巢浆液性肿瘤中血管内皮生长因子的表达及临床意义

Expression of vascular endothelial growth factor in ovarian serous neoplasms
下载PDF
导出
摘要 目的探讨卵巢浆液性肿瘤组织中血管内皮生长因子的表达的临床意义。方法采用免疫组化方法检测76例卵巢浆液性肿瘤(良性10例、交界性8例及恶性58例)中血管内皮生长因子(VEGF)的表达,并分析其与主要临床病理参数及卵巢癌患者预后的关系。结果VEGF的表达在良性、交界性及卵巢浆液性肿瘤中分别为(16.1±3.9)%、(36.7±14.2)%及(52.3±22.8)%,呈逐渐增高趋势,各组间比较差异有统计学意义;VEGF的表达在浆液性卵巢癌高、中及低分化组织中的表达分别为(30.9±16.2)%、(48.0±18.4)%及(62.1±21.3)%,组织分化愈差,其表达就愈高,各组间比较差异有统计学意义;VEGF的表达在浆液性卵巢癌Ⅰ-Ⅱ期及Ⅲ-Ⅳ期FIGO分期中分别为(40.0±18.0)%及(55.1±22.9)%,分期愈晚表达愈高,差异有统计学意义;浆液性卵巢癌组织中VEGF的表达与患者预后有关,高表达者预后差。结论VEGF在浆液性卵巢肿瘤的发生、发展中起重要促进作用,浆液性卵巢癌组织中VEGF表达对预测患者预后有一定价值。 Objective To study the expression of vascular endothelial growth factor(VEGF)in ovarian serous neoplasms and its significance. Methods Immunohistochemical method was used to examine the expression of VEGF in 76 cases of serous ovarian neoplasms.The relationship between VEGF expression and histopathological parameters,prognosis were investigated.Results VEGF expression was significantly higher in bordline cystadenomas than in cystadenomas,but significantly lower than in cystadenocarcinomas.In serous ovarian carcinoma,the worse tissual differentiation was,the higher expression of VEGF was.The expression of VEGF was significantly higher in the advanced caicinomas than that in the earlier ones.VEGF expression was negatively related to prognosis. Conclusion VEGF could promote the development of serous ovarian neoplasams,and may be a valuable prognostic indicator in serous ovarian cystadenocarcinomas.
出处 《山西医科大学学报》 CAS 2008年第5期426-429,481,共5页 Journal of Shanxi Medical University
关键词 卵巢浆液性肿瘤 血管内皮生长因子 预后 serous ovarian neoplasm vascular endothelial growth factor prognosis
  • 相关文献

参考文献13

  • 1Folkman J. Tumor angiogenesis: Therupeutic implications [J]. N Engl J Med,1971,285:1182-1186.
  • 2Ferrara N. Vascular endothelial growth factor:molecular and biological aspect[J ]. Curr Top Microbiol Immunol, 1999,237 : 1 - 30.
  • 3Olson TA, Mohanaraj D, Carson LF, et al. Vascular permeability factor gene expression in normal and neoplastic human ovaries [J].Cancer Res, 1994,54:276 280.
  • 4Garzetti GG, Ciavattini A, Lucarini G, et al. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with M1B1 immunostaining [J ]. Gynecol Oncol, 1999,73 : 396 - 401.
  • 5Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer [J]. Anticancer Res, 2001,21 (6B): 4373-4382.
  • 6Hanahan D, Folkman J. Pattems and emerging mechanisms of the angingenic seich during tumorigenesis[J]. Cell, 1996, 86 (3) :353 - 364.
  • 7Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor(vascular endothelial growth factor) and its receptor in ovarian borderline and malignant neoplasms [J]. Lab Invest, 1996,74:1105 - 1115.
  • 8Ramakrishnan S, Olson TA, Bauch VL, et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo [J ]. Cancer Res, 1996,56 : 1324 - 1330.
  • 9Fujimoto J, Ichigo S, Hori M, et al. Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers[J]. Eur J Gynaecol Oncol, 1997,18(5) :349 - 352.
  • 10Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients[J ]. Br J Cancer, 1997,76(2) :238 - 243.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部